RxDoctor Payments DataLook up a doctor →

Washington Muro, MD

Internal Medicine · Grandview, MONPI 1932218013

Payments from drug & device makers

$26,617in general payments, 2019–2025

Across 1,384 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$26,511100%
  • Education$1060%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca118$3,368
AbbVie(2 entities)200$3,258
Novo Nordisk110$1,836
Amgen(2 entities)71$1,645
Lilly USA, LLC110$1,455
Pfizer103$1,362
GSK64$1,173
Abbott38$990
Boehringer Ingelheim64$936
Corium, LLC27$870
Bayer27$776
Amarin Pharma, Inc.35$749
Johnson & Johnson29$572
Otsuka America Pharmaceutical, Inc.21$531
Takeda Pharmaceuticals U.S.A., Inc.37$529
Antares Pharma, Inc.37$494
Merck30$450
Astellas Pharma US Inc21$418
Eisai Inc.14$371
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$362
Esperion Therapeutics, Inc.14$325
Sumitomo Pharma America, Inc.13$309
Kowa Pharmaceuticals America, Inc.16$287
Axsome Therapeutics, Inc.6$269
Daiichi Sankyo Inc.8$226
Adlon Therapeutics L.p.14$196
Phathom Pharmaceuticals, Inc.5$190
Watermark Medical, Inc.1$189
Novartis7$179
Angiodynamics, Inc.2$171
Biohaven Pharmaceuticals, Inc.9$150
Medtronic1$133
Tris Pharma Inc2$129
Boston Scientific5$125
Xeris Pharmaceuticals, Inc.7$125
Bausch Health US, LLC8$120
Teva Pharmaceuticals USA, Inc.8$112
Organon2$108
Halozyme Inc5$80
Clarus Therapeutics Inc.8$80
Mannkind Corporation5$78
Cequr Corporation1$67
Zyla Life Sciences, Inc.6$67
Supernus Pharmaceuticals, Inc.3$61
Pharming Healthcare, Inc.3$57
Biohaven Pharmaceutical Holding Company Ltd.4$53
Shire North American Group Inc3$50
Sanofi Pasteur Inc.3$41
Lundbeck LLC2$41
Nevro Corp.2$38
E.r. Squibb & Sons, L.L.C.3$37
Alnylam Pharmaceuticals Inc.2$30
Impel Pharmaceuticals Inc.2$29
Exact Sciences2$28
Saluda Medical Americas, Inc.1$23
Radius Health, Inc.1$21
Sanofi-aventis U.S. LLC1$21
Dexcom, Inc.1$18
Neurelis, Inc.1$17
VBI Vaccine (delaware) Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,617 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$175,363
Medicare patients
435
Services billed
6,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$60,264
GlyxambiEmpagliflozin/Linagliptin43$58,154
OzempicSemaglutide41$47,880
JardianceEmpagliflozin26$42,676
XareltoRivaroxaban36$29,337
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$24,513
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$22,480
ProliaDenosumab12$20,687
MyrbetriqMirabegron23$18,878
MounjaroTirzepatide17$18,103
JanuviaSitagliptin Phosphate23$16,828
RexultiBrexpiprazole13$9,612
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$8,153
XyostedTestosterone Enanthate13$7,983
Atorvastatin Calcium705$6,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance, Stiolto Respimat$936$108,98381 claims
PfizerEliquis$1,362$60,26438 claims
Novo NordiskOzempic$1,836$47,88041 claims
Johnson & JohnsonXarelto$572$29,33736 claims
GSKTrelegy Ellipta$1,173$24,51328 claims
AstraZenecaBreztri Aerosphere$3,368$22,48033 claims
AmgenProlia$1,645$20,68712 claims
Astellas Pharma US IncMyrbetriq$418$18,87823 claims
Lilly USA, LLCMounjaro$1,455$18,10317 claims
MerckJanuvia$450$16,82823 claims
Otsuka America Pharmaceutical, Inc.Rexulti$531$9,61213 claims
Antares Pharma, Inc.Xyosted$494$7,98313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Grandview

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →